REVIEW

Recent advances in alcoholic hepatitis [version 1; peer review: 3 approved]

Vikrant Rachakonda, Ramon Bataller, Andres Duarte-Rojo

Division of Gastroenterology and Hepatology, Starzl Transplantation Institute, and Pittsburgh Liver Research Center, University of Pittsburgh, Pittsburgh, PA, 15213, USA

V1 First published: 10 Feb 2020, 9(F1000 Faculty Rev):97
<https://doi.org/10.12688/f1000research.20394.1>

Latest published: 10 Feb 2020, 9(F1000 Faculty Rev):97
<https://doi.org/10.12688/f1000research.20394.1>

Abstract

Alcoholic hepatitis is the severest clinical presentation of alcoholic liver disease. Lacking an effective pharmacologic treatment, alcoholic hepatitis is associated with a poor prognosis and its recovery relies mostly on abstinence. With alcohol use disorder being universally on the rise, the impact of alcoholic hepatitis on society and health-care costs is expected to increase significantly. Prognostic factors and liver biopsy can help with timely diagnosis, to determine eligibility and response to corticosteroids, and for prognostication and transplant referral. Although recent discoveries in the pathophysiology of alcoholic hepatitis are encouraging and could pave the way for novel treatment modalities, a multidisciplinary approach considering timely identification and treatment of liver-related complications, infectious and metabolic disease, malnutrition, and addiction counseling should be emphasized. Apart from proper selection of candidates, transplant programs should provide adequate post-transplant addiction support in order to make of early liver transplantation for alcoholic hepatitis the ultimate sobering experience in the next decade.

Keywords

addiction, corticosteroids, biomarkers, liver transplantation

Open Peer Review

Approval Status

	1	2	3
version 1 10 Feb 2020			

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Suthat Liangpunsakul**, Indiana University School of Medicine, Indianapolis, USA
2. **Sandeep Singh Sidhu**, Dayanand Medical College and Hospital, Ludhiana, India
3. **Philip Augustine**, Ernakulam Medical Centre, Cochin, India

Any comments on the article can be found at the end of the article.

Corresponding author: Andres Duarte-Rojo (duarteroja@upmc.edu)

Author roles: **Rachakonda V:** Conceptualization, Investigation, Writing – Original Draft Preparation; **Bataller R:** Writing – Review & Editing; **Duarte-Rojo A:** Conceptualization, Investigation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: Work by RB is supported by the National Institute on Alcohol Abuse and Alcoholism [1U01AA026978-01, 1U01AA026972-01, 1U01AA026264-01].

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2020 Rachakonda V *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Rachakonda V, Bataller R and Duarte-Rojo A. **Recent advances in alcoholic hepatitis [version 1; peer review: 3 approved]** F1000Research 2020, 9(F1000 Faculty Rev):97 <https://doi.org/10.12688/f1000research.20394.1>

First published: 10 Feb 2020, 9(F1000 Faculty Rev):97 <https://doi.org/10.12688/f1000research.20394.1>

Introduction

Alcoholic hepatitis (AH) is a life-threatening form of acute-on-chronic liver failure that occurs in patients with sustained heavy alcohol use. AH is characterized by a rapid onset or worsening of jaundice, liver synthetic dysfunction, and features of hepatic decompensation, including ascites, encephalopathy, and portal hypertensive bleeding. An episode of AH is frequently the first clinical presentation of alcohol-related liver disease, and in patients with severe disease, prognosis is poor; mortality is 20 to 50% at 28 days and up to 70% at 90 days^{1,2}. Pharmacotherapy for AH remains limited to corticosteroids; however, almost half of patients cannot tolerate or do not respond to corticosteroid therapy. The only intervention shown to improve long-term survival in AH is alcohol abstinence, thus highlighting a critical role for multidisciplinary care incorporating mental health and addiction teams. More recently, early liver transplantation (LT) has been used in carefully selected populations showing 3-year survival rates equivalent to those for other chronic liver diseases; concerns regarding post-transplant alcohol relapse, however, have limited acceptance of early transplantation as standard treatment.

Epidemiology of alcoholic hepatitis

The epidemiology of AH is poorly understood, particularly in the US, where liver biopsy is rarely performed for this condition. Trends in patterns of alcohol use, however, suggest that AH incidence rates are likely to increase in Western nations. Recent US reports on the impact of state alcohol sales policies have highlighted increased rates of alcohol consumption^{3,4}. Furthermore, drinking at an earlier age^{5,6} and bingeing patterns of use have dramatically increased in the last decade⁷. These behaviors have translated into increased mortality related to alcoholic liver disease; from 2009 to 2016, Americans 25 to 34 years old experienced the greatest increase in liver-related mortality among all age groups and this increase was driven entirely by alcoholic liver disease⁸. Although a significant proportion of these deaths are likely attributable to AH, no US studies have systematically explored the epidemiology of AH. In a Danish national cohort study, the incidence of AH rose from 24 to 34 per million women and from 37 to 46 per million men between 1999 and 2008⁹, and it is likely that similar trends have occurred in other Western nations.

With the changing epidemiology of alcohol use and alcohol-related liver disease, the health-care and economic burden of AH has increased over the last decade. For example, an analysis of the Nationwide Inpatient Sample demonstrated increased rates of hospitalization for AH from 2002 to 2010¹⁰. While there was a significant decline in inpatient mortality due to AH (4.3% absolute risk reduction), the cost of hospitalization increased by 41%¹⁰. Another report showed a 96% increase in the inpatient for both studies, increased costs likely represent an cost of care for alcoholic cirrhosis between 2002 and 2014, representing almost 50% of the total inpatient charges for cirrhosis¹¹. As length of stay remained unchanged over the studied time frame for both studies, increased costs likely represent an absolute increase in resource utilization.

Pathophysiology of alcoholic hepatitis

AH is driven by both intra- and extra-hepatic effects of alcohol. Within hepatocytes, alcohol is degraded into the toxic metabolite

acetaldehyde via non-inducible (alcohol dehydrogenase) and inducible (CYP2E1) enzymes. In addition to acetaldehyde, multiple reactive oxygen intermediates (ROIs) are generated by CYP2E1. Acetaldehyde directly induces hepatocyte death through both necrosis and apoptosis, and hepatocyte injury leads to release of damage-associated molecular patterns (DAMPs). DAMPs subsequently bind to Toll-like receptors (TLRs) in Kupffer cells, the resident tissue macrophage of the liver, leading to activation of the inflammasome, a multiprotein complex containing caspase 1. Upon inflammasome activation, caspase 1 generates the pro-inflammatory cytokine interleukin 1 beta (IL-1 β)¹²⁻¹⁴.

Alcohol exerts deleterious intestinal effects, which eventually lead to hepatic inflammation through multiple mechanisms. Particularly, alcohol exerts direct toxicity on intestinal epithelial cells and decreases the expression of tight-junction proteins, which enhances the permeability of the intestinal mucosa, permitting translocation of pathogen-associated molecular patterns (PAMPs) such as lipopolysaccharide (LPS) into the liver¹⁵⁻¹⁷. As with DAMPs, PAMPs can then activate macrophage inflammasomes via TLR, leading to elaboration of multiple inflammatory cytokines (including IL-1 β , tumor necrosis factor alpha (TNF- α) and IL-10) and neutrophil chemokines (including IL-8, Gro- α , CXCL-5, and CXCL-6)¹⁸. The net increase in intra-hepatic inflammation perpetuates further hepatocellular mitochondrial dysfunction, ROI generation, and hepatic failure.

In addition to dysregulated hepatic inflammation, multiple clinical observations point to hepatocellular dysfunction and impaired regeneration as critical drivers of liver failure in AH. First, liver explants from AH patients undergoing LT demonstrate near complete loss of hepatocyte proliferation compared with alcoholic cirrhosis and normal liver^{19,20}. In addition, hepatocyte proliferation is associated with improved survival in severe AH²⁰. Finally, patients with AH exhibit a significant expansion of liver progenitor cells (LPCs) (termed ductular reaction) and failure of LPC differentiation into mature hepatocytes correlates with reduced survival²¹. To further delineate molecular mechanisms of hepatocellular dysfunction in AH, Argemi *et al.* performed untargeted RNA sequencing in livers with different alcoholic liver disease phenotypes and identified that development of AH was characterized by defective activity of liver-enriched transcription factors²². In particular, transforming growth factor beta 1 (TGF- β 1) was a primary transcriptional regulator in AH and induced fetal isoforms of hepatic nuclear factor 4a (HNF-4a) P2 promoter, resulting in defective hepatic synthetic and metabolic function. Altered expression of HNF-4a-dependent genes was driven by epigenetic phenomena²². Together, these findings highlight a critical role for not only intra-hepatic inflammation but also hepatocellular dysfunction and impaired regeneration in the pathogenesis of AH.

Recently, genetic predisposition has expanded our understanding of alcoholic liver disease, and some relevant genetic signals are shared with the non-alcoholic steatohepatitis counterpart (for example, patatin-like phospholipase domain-containing protein 3, transmembrane 6 superfamily member 2, and hydroxysteroid 17-beta dehydrogenase 13)²³⁻²⁵. Although the impact of genetic predisposition in AH is less clear, mutations in

CYP2E1²⁶ and, more recently, a transcriptome analysis were over represented in AH or had prognostic implications²⁷. In the latter, a 123-gene prognostic signature was identified from fixed liver biopsy samples in patients with severe AH and it improved the prediction of transplant-free survival along with the model for end-stage liver disease (MELD). The identified genetic signals corresponded to inflammatory and oxidative stress pathways, intermediate metabolism, and hepatic stellate cells²⁷.

Gut dysbiosis has been involved in the pathophysiology of various chronic liver ailments, including alcoholic liver disease²⁸. Alcohol directly contributes to intestinal microbial dysbiosis, and in both murine and human studies, alcohol induces shifts in bacterial communities favoring pathogenic species^{29,30}. Non-bacterial populations are also affected, as a recent translational study described reduced fungal biodiversity with enhanced anti-fungal immune responses in severe AH³¹. Such changes in microbiota break the balance of the gut–liver axis either directly through bacterial metabolites or indirectly through TLRs and other signaling molecules (PAMP/DAMP pathways) and activation of the immune system³². The beneficial effects that modulation of the intestinal flora brings to patients with AH, as observed in pilot trials using either rifaximin or fecal microbiota transplantation, add evidence to support the pivotal role of the gut–liver axis and gut eubiosis as a novel therapeutic aim^{33,34}.

Diagnostic and prognostic assessment in alcoholic hepatitis

There are no reliable non-invasive markers for identification of AH and hence the syndrome is most often diagnosed on clinical grounds. The cardinal feature of AH is recent onset of jaundice within 60 days of last alcohol consumption in a patient with known heavy alcohol use for more than 6 months. The diagnosis relies on proving heavy alcohol use as the primary etiology of liver injury while excluding other causes of liver disease. Although minimum alcohol use requirements for AH have not been described, a consumption threshold of at least three drinks (40 g) daily in women or at least four drinks (60 g) daily in men is most commonly used for inclusion in treatment studies in AH. Laboratory features of AH include serum bilirubin of at least 3 mg/dL, aspartate aminotransferase (AST) between 50

and 400 IU/mL, and AST/alanine aminotransferase ratio of at least 1.5.

In 2016, an expert panel within the National Institute for Alcohol Abuse and Alcoholism proposed a classification scheme for AH as follows: (1) definite AH: clinical criteria for diagnosis are met and confirmed by liver biopsy; (2) probable AH: clinically diagnosed AH without liver biopsy and without confounding factors; and (3) possible AH: clinically diagnosed AH but with confounding factors, including possible ischemic hepatitis, drug-induced liver injury, atypical laboratory tests, or uncertainty regarding alcohol consumption or a combination of these²; in this subset, liver biopsy is recommended.

In contrast, the European Association for the Study of the Liver recommends liver biopsy for the diagnosis of AH, as the accuracy of clinical diagnosis is around 70 to 80%³⁵. Typical histologic findings include macrovesicular steatosis, ballooning degeneration of hepatocytes, Mallory–Denk bodies, megamitochondria, lobular inflammation with neutrophilic satellitosis, and bilirubinostasis with ductular reaction^{35–37}. Advanced fibrosis is a common feature of AH, and it is estimated that 80% of patients with AH have micronodular cirrhosis³⁷. Typical fibrosis patterns include centrilobular, pericellular, and sinusoidal fibrosis (“chicken wire” fibrosis). A landmark study from 2014 demonstrated that, in addition to prognostic information, histology may also provide prognostic value in AH, and a scoring system consisting of fibrosis, bilirubinostasis, neutrophilic infiltration, and megamitochondria demonstrated an area under the receiver operating characteristic curve (AUROC) of 0.77 for 90-day mortality³⁷. Severe AH was defined as a histologic score of 6 to 9 and was associated with 50% 90-day mortality³⁷. Interestingly, severity of fibrosis was the strongest negative predictor of survival whereas neutrophilic inflammation was associated with improved survival. Despite the utility of liver biopsy, the presence of coagulopathy, thrombocytopenia, uremia, and ascites in AH generally precludes percutaneous liver biopsy, and transjugular biopsy is not widely available.

Several laboratory-based scoring systems have been studied for outcome prediction in AH and these are highlighted in Table 1.

Table 1. Prognostic scoring systems for alcoholic hepatitis.

Score	Formula				Interpretation
MDF	$4.6 \times (\text{PT} - \text{control PT}) + \text{bilirubin (mg/dL)}$				Severe: ≥ 32
MELD	$3.8 \times [\ln(\text{bilirubin (mg/dL)})] + 11.2 \times [\ln(\text{INR})] + 9.6 \times [\ln(\text{creatinine (mg/dL)})] + 6.4$				Severe: ≥ 21
ABIC	$(\text{age} \times 0.1) + (\text{bilirubin} \times 0.08)$				Low risk: ≤ 6.71 Severe: > 9.0
GAHS		1	2	3	Severe: ≥ 9
	Age	< 50	≥ 50	–	
	WBC count	< 15	≥ 15	–	
	Urea, mmol/L	< 5	≥ 5	–	
	INR	< 1.5	$1.5 - 2.0$	> 2.0	
	Bilirubin, mg/dL	< 7.3	$7.4 - 14.6$	> 14.6	

ABIC, age/bilirubin/international normalized ratio/creatinine; GAHS, Glasgow Alcoholic Hepatitis Score; INR, international normalized ratio; MDF, Maddrey discriminant function; MELD, Model for End-Stage Liver Disease; PT, prothrombin time; WBC, white blood cell.

Historically, the Maddrey discriminant function (MDF) was the most commonly used model to identify candidates for corticosteroid therapy³⁸. Two major drawbacks of MDF were (1) the use of prothrombin time, which is not standardized between clinical laboratories, and (2) the absence of renal function assessment, as acute kidney injury is a strong predictor of mortality in AH³⁹. More recently, the MELD score has been used to classify AH patients at high risk of death in need of treatment⁴⁰. At a cutoff of at least 21, MELD score exhibited 75% sensitivity and specificity for predicting 90-day mortality. Other models, including the age/bilirubin/international normalized ratio/creatinine (ABIC) score⁴¹ and the Glasgow Alcoholic Hepatitis Score (GAHS)⁴² are less well studied in North American populations. An ABIC score of less than 6.71 has been associated with 100% survival, whereas an ABIC score of more than 9.00 predicts 25% survival at 90 days⁴¹. The GAHS has also been used to identify candidates for corticosteroid therapy, as patients with a GAHS of at least 9 and an MDF of at least 32 exhibited better survival with steroid therapy than without, whereas subjects with a GAHS of less than 9 and an MDF of less than 32 did not benefit from treatment⁴³.

Early observational trials of steroid therapy identified declining bilirubin as a marker of therapeutic response and hence the Lille score was developed to quantify changes in labs over 7 days of steroid treatment. A Lille score of more than 0.45 after 7 days was associated with over 75% 90-day mortality⁴⁴. A multinational study reported on a similar accuracy when the Lille score was evaluated at day 4, when compared with the original one after 7 days on corticosteroids⁴⁵. Combining MELD and Lille scores increases prognostic accuracy compared with either score alone⁴⁶, and various useful combination strategies were recently studied as part of a *post hoc* analysis of a large multicenter AH clinical trial⁴⁷.

Given the above limitations of laboratory-based models for outcome prediction in AH, a number of studies have explored novel biomarkers of AH. For example, analysis of circulating exosomes has demonstrated increased enrichment of miR-155 (a key regulator of inflammation), miR-192, and miR-30a in patients with AH compared with controls^{48,49}. Circulating levels of several cytokines, including TNF- α , IL-1, IL-6, and IL-8, have also been studied in AH, and elevated serum IL-6 levels, in particular, have shown promise as a marker of increased mortality in patients with an MDF of at least 32⁵⁰. More recently, two studies have shown that increased levels of cytokeratin 18 fragments may be used for identification and severity assessment in AH^{51,52}, and urinary metabolomics studies have identified higher levels of urinary acrolein metabolites in severe AH compared with both healthy controls and non-severe disease⁵³. Finally, an analysis of blood neutrophil/lymphocyte ratio (NLR) demonstrated that NLR was associated with infection, acute kidney injury, and steroid responsiveness⁵⁴. Validation and standardization of these promising tools are still needed across multiple clinical settings.

Management of acute alcoholic hepatitis

The pharmacotherapy for AH has changed little since the introduction of corticosteroids in the early 1970s⁵⁵, and although an early

clinical trial demonstrated that pentoxifylline decreased short-term mortality by reducing rates of renal failure⁵⁶, the recently reported STOPAH (steroids or pentoxifylline for alcoholic hepatitis) study has raised concerns regarding the efficacy of both treatments⁵⁷. Over 1,100 patients were enrolled from hospitals throughout Britain and randomly assigned into a 2x2 factorial designed clinical trial to study the benefit of corticosteroids and pentoxifylline. Corticosteroids demonstrated a trend toward reduced 28-day mortality compared with placebo (14% versus 18%, $P = 0.06$), but no reduction was observed for 90-day mortality. Pentoxifylline provided no improvements in either short-term or long-term mortality. Importantly, mortality rates were significantly lower than those reported in other clinical trials of severe AH. As biopsy-proven AH was not used as an inclusion criterion, this raised concerns regarding whether a subset of patients had acute-on-chronic liver failure related to decompensated cirrhosis as opposed to AH. Two recent meta-analyses of randomized controlled trials reported that corticosteroids provided significant survival benefit at 28 days but not at 90 or 180 days^{58,59}, although the last updated Cochrane meta-analysis continues to find no benefit. Given the short-term benefits of corticosteroids, their judicious use is still warranted in selected populations.

There is increasing interest in novel treatments for severe AH (Table 2). Ongoing trials are exploring the efficacy of antibiotic therapy, farnesoid X receptor (FXR) agonists (obeticholic acid), caspase inhibitors (emricasan), receptor tyrosine kinase inhibitors (selonsertib), IL-1R antagonists (anakinra), and IL-22 agonists. Of particular interest is the use granulocyte-colony stimulating factor (G-CSF). The rationale for G-CSF is based on (1) histologic studies demonstrating that increased hepatic neutrophil infiltration is associated with improved survival in AH³⁷ and (2) pre-clinical observations that G-CSF mobilizes granulocytes to improve survival in acute-on-chronic liver failure⁶⁰. A few randomized pilot studies from India have shown increased survival and more rapid decline in MELD scores in both decompensated cirrhosis and AH^{61–65}. Though promising, these results will require replication in other clinical centers.

Supportive measures

Alcohol abstinence

Although corticosteroids marginally improve short-term mortality, only alcohol abstinence has been shown to increase 6-month survival^{66,67}. Most patients with AH meet criteria for an alcohol use disorder (AUD), characterized by ongoing alcohol consumption despite experiencing adverse consequences of drinking⁶⁸. Therefore, use of screening tools to diagnose AUDs in patients with AH is critical to guide referral to optimal treatment pathways. One recent meta-analysis of the AUD Identification Test-Consumption (AUDIT-C)⁶⁹ (<https://www.drugabuse.gov/sites/default/files/files/AUDIT.pdf>) demonstrated feasibility and efficacy of this instrument for identification of AUDs; furthermore, counseling interventions in those patients testing positive led to reductions in harmful alcohol consumption⁷⁰.

In addition to addiction counseling, pharmacotherapy for AUD is now available (Table 3). Although disulfiram and naltrexone have US Food and Drug Administration approval for treatment of AUD, both drugs exhibit significant hepatotoxicity limiting

Table 2. Recent/ongoing clinical trials for treatment of alcoholic hepatitis.

Agent	Mechanism of action	Study design	Inclusion criteria	Primary endpoint	ClinicalTrials.gov identifier and status
G-CSF	Hepatic neutrophil expansion, liver regeneration	Placebo-controlled RCT: + CS in PR No CS in NR	DF ≥ 32	NR: 2-month survival PR: 6-month survival	NCT02442180, phase IV, enrolling
OCA	FXR agonist	Placebo-controlled RCT	MELD 11–20	MELD change after 6 weeks	NCT02039219, phase II, completed
Amoxicillin/Clavulanic acid	Gut microbiome modulation, infection prevention	Placebo-controlled RCT with CS	MELD ≥ 21	2-month survival	NCT02281929, phase III, active, not enrolling
Emricasan	Caspase inhibitor	Placebo-controlled RCT	MELD 20–35 or MELD >35 plus SOFA <10	28-day survival	NCT01912404, phase II, terminated
Selonsertib	ASK-1 inhibitor, MAPK inhibitor	Placebo-controlled RCT with CS	DF ≥ 32	Safety at 28 days	NCT02854631, phase II, completed
Anakinra	IL-1R antagonist	RCT of Anakinra + Zinc + PTX versus CS alone	MELD ≥ 20 and DF ≥ 32	6-month survival	NCT01809132, phase II, completed
IL-22	Hepatic regeneration	Open-label	MELD 11–28	Safety at 42 days	NCT unavailable, phase I completed
FMT	Alleviates gut dysbiosis	Open-label	DF ≥ 32 and low-grade HE	3-month survival	NCT03827772, phase II, enrolling

ASK-1, apoptosis signal-regulating kinase-1; CS, corticosteroids; DF, discriminant function; FMT, fecal microbiota transplantation; FXR, farnesoid X receptor; G-CSF, granulocyte colony-stimulating factor; HE, hepatic encephalopathy; IL-1R, interleukin-1 receptor; IL-22, interleukin-22; MELD, Model for End-Stage Liver Disease; NR, non-responder; OCA, obeticholic acid; PR, partial responder; PTX, pentoxifylline; RCT, randomized controlled trial; SOFA, sequential organ failure assessment.

Table 3. Pharmacotherapy for alcohol use disorder.

Drug	Mechanism of action	Dose	Hepatic metabolism and risk of toxicity
FDA-approved			
Acamprosate	NDMA agonist	666 mg orally three times daily (333 mg with renal dysfunction)	No hepatic metabolism, adjust dose in kidney injury
Disulfiram	Acetaldehyde dehydrogenase inhibitor	250–500 mg orally daily	No hepatic metabolism, associated with drug-induced liver injury
Naltrexone	Mu-opiate receptor antagonist	50 mg orally daily or 380 mg intra-muscularly monthly	Hepatocellular injury described
Not FDA-approved			
Baclofen	GABA-B receptor agonist	Up to 80 mg daily orally in divided doses	Minimal hepatic metabolism; formally studied in cirrhosis
Gabapentin	GABA modulator	900–1800 mg daily in divided doses	No hepatic metabolism; sedation risk in cirrhotic patients with hepatic encephalopathy
Topiramate	Anticonvulsant	300 mg orally daily	Partial hepatic metabolism via glucoronidation
Varenicline	Nicotinic receptor agonist	2 mg orally daily	Minimal hepatic metabolism

FDA, US Food and Drug Administration; GABA, gamma aminobutyric acid; NMDA, N-methyl-D-aspartate.

their use in advanced liver disease. Baclofen has been studied extensively for AUD treatment in patients. Given the limited hepatic metabolism of baclofen, there is a theoretically lower risk of hepatotoxicity. Results of baclofen treatment trials, however, are mixed⁷¹. Whereas one meta-analysis of 14 studies demonstrated no superiority of baclofen over placebo⁷², two other meta-analyses demonstrated increased rates of abstinence and increased time to first relapse with baclofen^{73,74}. Other drugs with low reported risk of hepatic injury include acamprostate, gabapentin, topiramate, and varenicline. However, of these agents, only acamprostate is approved for treatment of AUD. A recent meta-analysis demonstrated reduced rates of alcohol relapse for acamprostate (number needed-to-treat of 12; 27 trials)⁷⁵. Although further trials are needed to assess efficacy specifically in alcoholic liver disease, acamprostate represents an alternative therapeutic option in survivors of an episode of severe AH.

Identification and treatment of infections

Infections are a common complication of AH and contribute to increased mortality in AH⁷⁶. In the STOPAH trial, infections were responsible for 24% of all deaths⁵⁷. Patients with severe AH are at particularly increased risk for infection for a number of reasons. First, immune function of circulating innate immune cells is impaired, as multiple studies have identified decreased phagocytic activity, oxidative burst, and proliferation in severe AH^{77,78}. Second, immunosuppression with corticosteroids impacts infection risk, as shown in a subanalysis of the STOPAH trial where circulating bacterial DNA detected at enrollment was associated with development of early infections (within 7 days of commencing treatment) only among patients who received prednisolone⁷⁹. The source and type of infection also change during the disease course. In an early study of AH, spontaneous bacterial peritonitis and spontaneous bacteremia were leading infections at initial presentation whereas respiratory infections were the most common infections after exposure to corticosteroids⁸⁰. Although Gram-negative bacteria are the leading organisms identified in AH, recent studies have reported invasive fungal infections. For example, in a series of 120 consecutive AH patients admitted to an intensive care unit, 10% developed invasive fungal infections, including candidemia and invasive aspergillosis infections; all were exposed to corticosteroids⁸¹.

Finally, early diagnosis of infection in AH is particularly challenging in patients with systemic inflammatory response syndrome (SIRS), which is diagnosed when two or more of the following criteria are met: (a) white blood cell count of more than 12,000/mL or less than 4,000/mL or more than 10% bands, (b) temperature of more than 38°C or less than 36°C, (c) heart rate of more than 90 beats/minute, (d) respiratory rate of more than 20/minute. In one study, SIRS was present in 20% of patients at admission and was associated with multiple organ failure and short-term death⁸² independent of the presence of infection. Owing to the high rate of negative bacterial cultures in AH patients with SIRS, there is growing interest in the development of novel infection biomarkers in AH. Small studies have demonstrated efficacy of bacterial DNA and LPS^{79,82} to screen for infections, but further research is needed to validate these findings. As up to 26% of patients with AH initially present with

infection⁸⁰, baseline screening for infection (blood cultures, urine cultures, chest radiography, and ascitic fluid analysis) is routinely performed; furthermore, a clinical trial studying the use of amoxicillin/clavulanic acid with prednisolone in patients with severe AH was nearing completion by December 2019 (ClinicalTrials.gov identifier: NCT02281929).

Evaluation of nutritional status and nutritional support

Malnutrition—in particular, protein-calorie malnutrition—is a well-recognized complication of AH^{83,84}. With the rising epidemic of obesity in Western nations, a subjective physical assessment by treating clinicians may incorrectly classify nutritional status in severe AH. Although a recent randomized clinical trial failed to demonstrate intense enteral nutrition via nasogastric tube superior to oral nutrition in patients with AH treated with corticosteroids, a subgroup analysis showed that patients receiving less than 21.5 kcal/kg per day had lower 6-month survival than patients meeting this threshold, and reduced survival was associated with decreased protein and lipid content in the diet⁸⁵. In addition, multiple macro- and micro-nutrient deficiencies have been described in AH. In particular, zinc deficiency is associated with increased intestinal permeability⁸⁶, and a clinical trial incorporating zinc supplementation (ClinicalTrials.gov identifier: NCT01809132) was completed in December 2018.

Recently, there has been renewed interest in the use of objective measures of nutritional status and physical function for outcome prediction in cirrhosis. In patients with decompensated cirrhosis, 6-minute walk test, cross-sectional abdominal muscle area, and gait speed are strongly associated with mortality, LT waitlist dropout, and increased hospital-related expenditures^{87–89}. Furthermore, a liver frailty index composed of dominant grip strength, chair stands, and balance was recently shown to predict survival in decompensated cirrhosis⁹⁰. Although these tools have yet to be incorporated into prognostic models in AH, they may hold potential, in particular, for predicting long-term outcomes in short-term survivors of an episode of AH.

Early liver transplantation for alcoholic hepatitis

Patients with AH who fail corticosteroids have poor long-term survival, and some studies reported up to 75% 6-month mortality⁴⁴. Therefore, LT has emerged as a potential curative therapy for AH. Historically, transplantation for alcoholic liver disease has required demonstration of abstinence for at least 6 months. The genesis of the “6-month rule”, however, was to permit recovery from an episode of acute-on-chronic liver failure after prolonged abstinence, but by the late 1990s, most US LT programs and insurance carriers required a 6-month abstinence period prior to approving LT listing. Multiple studies have examined the utility of the pre-transplant sobriety for predicting post-transplant relapse, but results have been conflicting. In one landmark analysis of LTs performed for alcoholic liver disease, steatohepatitis on explant pathology was used as a surrogate marker of recent alcohol consumption; interestingly, there were no differences in patient survival, graft survival, or alcohol relapse rates between subjects with and without steatohepatitis⁹¹. Also, a systematic review of 22 studies reported that duration of pre-transplant abstinence was a poor predictor of post-transplant

relapse⁹², although some reports have identified duration of pre-transplant sobriety as a predictor of post-transplant drinking^{93–95}. Interestingly, the United Network for Organ Sharing has never formally recommended a 6-month rule for transplant candidacy.

In a prospective, multi-center European trial, early LT for steroid non-responders afforded a marked survival benefit when compared with historical matched controls (6-month survival of 77% versus 23%, respectively; $P < 0.001$)⁹⁶. Importantly, these transplants accounted for only 2.9% of all transplants performed at participating centers over the same period, thus allaying concerns regarding reduced donor availability for other liver diseases. Since this report, a number of single-center studies have reported similar survival benefit^{97,98}. In particular, a recent US series of 147 LT recipients across 12 centers demonstrated a 3-year survival of 84%, and survival was 100% in patients who maintained sobriety after LT⁹⁹. Outcome modeling using data from the two seminal trials showed that early transplantation improves survival when compared with the 6-month probation—regardless of estimated post-transplant alcohol recidivism—and the highest survival advantage was among patients with a Lille score of 0.5 to 0.82 and a MELD score of at least 32¹⁰⁰.

Reported psychosocial selection criteria across transplant centers are variable but appear to adhere to the following principles: (1) adequate psychosocial support, (2) a first episode

of hepatic decompensation related to alcohol use, (3) absence of other substance use disorders, (4) absence of untreated psychiatric disease, and (5) acknowledgment of an AUD and willingness to participate in alcohol rehabilitation to maintain abstinence after LT. More recently, a model for alcohol relapse after LT identified prior alcohol-related legal issues and multiple failed alcohol rehabilitation attempts as additional risk factors^{99,101}. Future studies are needed to optimize uniform selection criteria to (1) maximize long-term abstinence in LT recipients with severe AH and (2) ensure equity and fairness in the care of patients with severe AH.

Conclusions

AH is a life-threatening form of acute-on-chronic liver failure in patients with chronic heavy alcohol use. Given temporal trends in alcohol consumption patterns worldwide, the incidence of AH, especially in young adults, is expected to rise in the next decade. Despite high rates of short-term mortality in severe AH, the treatment of AH and accompanying AUD has remained largely unchanged since the 1970s. A marked increase in the number of diagnostic and therapeutic trials in the last decade, however, reflects a growing interest in this devastating disease. LT is a life-saving therapeutic option for AH and is to be encouraged particularly in patients with a favorable profile and low risk for alcohol recidivism. Future studies should aim to improve post-transplant addiction support in order to maximize transplant benefits.

References

- Singal AK, Kamath PS, Gores GJ, *et al.*: **Alcoholic hepatitis: current challenges and future directions.** *Clin Gastroenterol Hepatol.* 2014; **12**(4): 555–64; quiz e31–2.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Crabb DW, Battaller R, Chalasani NP, *et al.*: **Standard Definitions and Common Data Elements for Clinical Trials in Patients With Alcoholic Hepatitis: Recommendation From the NIAAA Alcoholic Hepatitis Consortia.** *Gastroenterology.* 2016; **150**(4): 785–90.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Xuan Z, Nelson TF, Heeren T, *et al.*: **Tax policy, adult binge drinking, and youth alcohol consumption in the United States.** *Alcohol Clin Exp Res.* 2013; **37**(10): 1713–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Yörük BK: **Legalization of Sunday alcohol sales and alcohol consumption in the United States.** *Addiction.* 2014; **109**(1): 55–61.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Siegel M, DeJong W, Naimi TS, *et al.*: **Alcohol brand preferences of underage youth: results from a pilot survey among a national sample.** *Subst Abus.* 2011; **32**(4): 191–201.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Siegel MB, Naimi TS, Creameens JL, *et al.*: **Alcoholic beverage preferences and associated drinking patterns and risk behaviors among high school youth.** *Am J Prev Med.* 2011; **40**(4): 419–26.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Bor J, Basu S, Coutts A, *et al.*: **Alcohol use during the great recession of 2008–2009.** *Alcohol Alcohol.* 2013; **48**(3): 343–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
- F** Tapper EB, Parikh ND: **Mortality due to cirrhosis and liver cancer in the United States, 1999–2016: observational study.** *BMJ.* 2018; **362**: k2817.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- Sandahl TD, Jepsen P, Thomsen KL, *et al.*: **Incidence and mortality of alcoholic hepatitis in Denmark 1999–2008: a nationwide population based cohort study.** *J Hepatol.* 2011; **54**(4): 760–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Jinjuvadia R, Liangpunsakul S, Translational Research and Evolving Alcoholic Hepatitis Treatment Consortium: **Trends in Alcoholic Hepatitis-related Hospitalizations, Financial Burden, and Mortality in the United States.** *J Clin Gastroenterol.* 2015; **49**(6): 506–11.
[PubMed Abstract](#) | [Free Full Text](#)
- Barritt AS, Jiang Y, Schmidt M, *et al.*: **Charges for Alcoholic Cirrhosis Exceed All Other Etiologies of Cirrhosis Combined: A National and State Inpatient Survey Analysis.** *Dig Dis Sci.* 2019; **64**(6): 1460–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Nagy LE: **The Role of Innate Immunity in Alcoholic Liver Disease.** *Alcohol Res.* 2015; **37**(2): 237–50.
[PubMed Abstract](#) | [Free Full Text](#)
- Petrasek J, Csak T, Szabo G: **Toll-like receptors in liver disease.** *Adv Clin Chem.* 2013; **59**: 155–201.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Gao B, Battaller R: **Alcoholic liver disease: pathogenesis and new therapeutic targets.** *Gastroenterology.* 2011; **141**(5): 1572–85.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Yin H, Hu M, Zhang R, *et al.*: **MicroRNA-217 promotes ethanol-induced fat accumulation in hepatocytes by down-regulating SIRT1.** *J Biol Chem.* 2012; **287**(13): 9817–26.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- F** Leclercq S, Matamoros S, Cani PD, *et al.*: **Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity.** *Proc Natl Acad Sci U S A.* 2014; **111**(42): E4485–E4493.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- Parlesak A, Schäfer C, Schütz T, *et al.*: **Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease.** *J Hepatol.* 2000; **32**(5): 742–7.
[PubMed Abstract](#) | [Publisher Full Text](#)

18. Dominguez M, Miquel R, Colmenero J, *et al.*: **Hepatic expression of CXC chemokines predicts portal hypertension and survival in patients with alcoholic hepatitis.** *Gastroenterology*. 2009; **136**(5): 1639–50.
[PubMed Abstract](#) | [Publisher Full Text](#)
19. Dubuquoy L, Louvet A, Lassailly G, *et al.*: **Progenitor cell expansion and impaired hepatocyte regeneration in explanted livers from alcoholic hepatitis.** *Gut*. 2015; **64**(12): 1949–60.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
20. **F** Lanthier N, Rubbia-Brandt L, Lin-Marq N, *et al.*: **Hepatic cell proliferation plays a pivotal role in the prognosis of alcoholic hepatitis.** *J Hepatol*. 2015; **63**(3): 609–21.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
21. Sancho-Bru P, Altamirano J, Rodrigo-Torres D, *et al.*: **Liver progenitor cell markers correlate with liver damage and predict short-term mortality in patients with alcoholic hepatitis.** *Hepatology*. 2012; **55**(6): 1931–41.
[PubMed Abstract](#) | [Publisher Full Text](#)
22. Argemi J, Lataste MU, Atkinson SR, *et al.*: **Defective HNF4alpha-dependent gene expression as a driver of hepatocellular failure in alcoholic hepatitis.** *Nat Commun*. 2019; **10**(1): 3126.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
23. **F** Abul-Husn NS, Cheng X, Li AH, *et al.*: **A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease.** *N Engl J Med*. 2018; **378**(12): 1096–106.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
24. **F** Tian C, Stokowski RP, Kershenovich D, *et al.*: **Variant in PNPLA3 is associated with alcoholic liver disease.** *Nat Genet*. 2010; **42**(1): 21–3.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
25. Buch S, Stickel F, Trépo E, *et al.*: **A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis.** *Nat Genet*. 2015; **47**(12): 1443–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
26. Segado Soriano A, Santiago Dorrego C, Bañares Cañizares R, *et al.*: **[Genetic susceptibility to the development of acute alcoholic hepatitis: role of genetic mutations in dehydrogenase alcohol, aldehyde dehydrogenase and cytochrome P450 2E1].** *Rev Clin Esp*. 2005; **205**(11): 528–32.
[PubMed Abstract](#) | [Publisher Full Text](#)
27. **F** Trépo E, Goossens N, Fujiwara N, *et al.*: **Combination of Gene Expression Signature and Model for End-Stage Liver Disease Score Predicts Survival of Patients With Severe Alcoholic Hepatitis.** *Gastroenterology*. 2018; **154**(4): 965–75.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
28. Bajaj JS: **Alcohol, liver disease and the gut microbiota.** *Nat Rev Gastroenterol Hepatol*. 2019; **16**(4): 235–46.
[PubMed Abstract](#) | [Publisher Full Text](#)
29. Llopis M, Cassard AM, Wrzosek L, *et al.*: **Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease.** *Gut*. 2016; **65**(5): 830–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
30. **F** Lowe PP, Gyongyosi B, Sathishchandran A, *et al.*: **Alcohol-related changes in the intestinal microbiome influence neutrophil infiltration, inflammation and steatosis in early alcoholic hepatitis in mice.** *PLoS One*. 2017; **12**(3): e0174544.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
31. Lang S, Duan Y, Liu J, *et al.*: **Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients With Alcoholic Hepatitis.** *Hepatology*. 2019.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
32. **F** Konturek PC, Harsch IA, Konturek K, *et al.*: **Gut–Liver Axis: How Do Gut Bacteria Influence the Liver?** *Med Sci (Basel)*. 2018; **6**(3): pii: E79.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
33. Jimenez C, Ventura M, Sala M, *et al.*: **Use of rifaximin in alcoholic hepatitis: Pilot study.** *J Hepatol*. 2018; **68**: S816.
[Publisher Full Text](#)
34. **F** Philips CA, Pande A, Shasthry SM, *et al.*: **Healthy Donor Fecal Microbiota Transplantation in Steroid-Ineligible Severe Alcoholic Hepatitis: A Pilot Study.** *Clin Gastroenterol Hepatol*. 2017; **15**(4): 600–2.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
35. European Association for the Study of Liver: **EASL clinical practical guidelines: management of alcoholic liver disease.** *J Hepatol*. 2012; **57**(2): 399–420.
[PubMed Abstract](#) | [Publisher Full Text](#)
36. Lucey MR, Mathurin P, Morgan TR: **Alcoholic hepatitis.** *N Engl J Med*. 2009; **360**(26): 2758–69.
[PubMed Abstract](#) | [Publisher Full Text](#)
37. Altamirano J, Miquel R, Katoonizadeh A, *et al.*: **A histologic scoring system for prognosis of patients with alcoholic hepatitis.** *Gastroenterology*. 2014; **146**(5): 1231–1239.e6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
38. Maddrey WC, Boitnott JK, Bedine MS, *et al.*: **Corticosteroid therapy of alcoholic hepatitis.** *Gastroenterology*. 1978; **75**(2): 193–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
39. Altamirano J, Fagundes C, Dominguez M, *et al.*: **Acute kidney injury is an early predictor of mortality for patients with alcoholic hepatitis.** *Clin Gastroenterol Hepatol*. 2012; **10**(1): 65–71.e3.
[PubMed Abstract](#) | [Publisher Full Text](#)
40. Dunn W, Jamil LH, Brown LS, *et al.*: **MELD accurately predicts mortality in patients with alcoholic hepatitis.** *Hepatology*. 2005; **41**(2): 353–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
41. Dominguez M, Rincón D, Abalde JG, *et al.*: **A new scoring system for prognostic stratification of patients with alcoholic hepatitis.** *Am J Gastroenterol*. 2008; **103**(11): 2747–56.
[PubMed Abstract](#) | [Publisher Full Text](#)
42. Forrest EH, Evans CD, Stewart S, *et al.*: **Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score.** *Gut*. 2005; **54**(8): 1174–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
43. Forrest EH, Morris AJ, Stewart S, *et al.*: **The Glasgow alcoholic hepatitis score identifies patients who may benefit from corticosteroids.** *Gut*. 2007; **56**(12): 1743–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
44. **F** Louvet A, Naveau S, Abdelnour M, *et al.*: **The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids.** *Hepatology*. 2007; **45**(6): 1348–54.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
45. Garcia-Saenz-de-Sicilia M, Duvoor C, Altamirano J, *et al.*: **A Day-4 Lille Model Predicts Response to Corticosteroids and Mortality in Severe Alcoholic Hepatitis.** *Am J Gastroenterol*. 2017; **112**(2): 306–15.
[PubMed Abstract](#) | [Publisher Full Text](#)
46. Louvet A, Labreuche J, Artru F, *et al.*: **Combining Data From Liver Disease Scoring Systems Better Predicts Outcomes of Patients With Alcoholic Hepatitis.** *Gastroenterology*. 2015; **149**(2): 398–406.e8; quiz e16–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
47. **F** Forrest EH, Atkinson SR, Richardson P, *et al.*: **Application of prognostic scores in the STOPAH trial: Discriminant function is no longer the optimal scoring system in alcoholic hepatitis.** *J Hepatol*. 2018; **68**(3): 511–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
48. Momen-Heravi F, Saha B, Kodys K, *et al.*: **Increased number of circulating exosomes and their microRNA cargos are potential novel biomarkers in alcoholic hepatitis.** *J Transl Med*. 2015; **13**: 261.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
49. Szabo G, Bala S: **Reply: To PMID 22684891.** *Hepatology*. 2013; **57**(6): 2547.
[PubMed Abstract](#) | [Publisher Full Text](#)
50. Rachakonda V, Gabbert C, Raina A, *et al.*: **Stratification of risk of death in severe acute alcoholic hepatitis using a panel of adipokines and cytokines.** *Alcohol Clin Exp Res*. 2014; **38**(11): 2712–21.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
51. **F** Woolbright BL, Bridges BW, Dunn W, *et al.*: **Cell Death and Prognosis of Mortality in Alcoholic Hepatitis Patients Using Plasma Keratin-18.** *Gene Expr*. 2017; **17**(4): 301–12.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
52. Bissonnette J, Altamirano J, Devue C, *et al.*: **A prospective study of the utility of plasma biomarkers to diagnose alcoholic hepatitis.** *Hepatology*. 2017; **66**(2): 555–63.
[PubMed Abstract](#) | [Publisher Full Text](#)
53. **F** Vatsalya V, Kong M, Gobejishvili L, *et al.*: **Urinary acrolein metabolite levels in severe acute alcoholic hepatitis patients.** *Am J Physiol Gastrointest Liver Physiol*. 2019; **316**(1): G115–G122.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
54. **F** Forrest EH, Storey N, Sinha R, *et al.*: **Baseline neutrophil-to-lymphocyte ratio predicts response to corticosteroids and is associated with infection and renal dysfunction in alcoholic hepatitis.** *Aliment Pharmacol Ther*. 2019; **50**(4): 442–53.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
55. Porter HP, Simon FR, Pope CE, *et al.*: **Corticosteroid therapy in severe alcoholic hepatitis. A double-blind drug trial.** *N Engl J Med*. 1971; **284**(24): 1350–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
56. Akriviadis E, Botla R, Briggs W, *et al.*: **Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial.** *Gastroenterology*. 2000; **119**(6): 1637–48.
[PubMed Abstract](#) | [Publisher Full Text](#)
57. **F** Thursz MR, Richardson P, Allison M, *et al.*: **Prednisolone or pentoxifylline for alcoholic hepatitis.** *N Engl J Med*. 2015; **372**(17): 1619–28.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
58. Singh S, Murad MH, Chandar AK, *et al.*: **Comparative Effectiveness of Pharmacological Interventions for Severe Alcoholic Hepatitis: A Systematic Review and Network Meta-analysis.** *Gastroenterology*. 2015; **149**(4): 958–970.e12.
[PubMed Abstract](#) | [Publisher Full Text](#)
59. **F** Louvet A, Thursz MR, Kim DJ, *et al.*: **Corticosteroids Reduce Risk of Death Within 28 Days for Patients With Severe Alcoholic Hepatitis, Compared With Pentoxifylline or Placebo—a Meta-analysis of Individual Data From Controlled Trials.** *Gastroenterology*. 2018; **155**(2): 458–468.e8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
60. Garg V, Garg H, Khan A, *et al.*: **Granulocyte colony-stimulating factor mobilizes CD34+ cells and improves survival of patients with acute-on-chronic liver failure.** *Gastroenterology*. 2012; **142**(3): 505–512.e1.
[PubMed Abstract](#) | [Publisher Full Text](#)
61. **F** Kedarisetty CK, Anand L, Bhardwaj A, *et al.*: **Combination of granulocyte**

- colony-stimulating factor and erythropoietin improves outcomes of patients with decompensated cirrhosis. *Gastroenterology*. 2015; 148(7): 1362–1370.e7. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
62. Singh V, Sharma AK, Narasimhan RL, *et al.*: Granulocyte colony-stimulating factor in severe alcoholic hepatitis: a randomized pilot study. *Am J Gastroenterol*. 2014; 109(9): 1417–23. [PubMed Abstract](#) | [Publisher Full Text](#)
 63. Spahr L, Lambert JF, Rubbia-Brandt L, *et al.*: Granulocyte-colony stimulating factor induces proliferation of hepatic progenitors in alcoholic steatohepatitis: a randomized trial. *Hepatology*. 2008; 48(1): 221–9. [PubMed Abstract](#) | [Publisher Full Text](#)
 64. **F** Singh V, Keisham A, Bhalla A, *et al.*: Efficacy of Granulocyte Colony-Stimulating Factor and N-Acetylcysteine Therapies in Patients With Severe Alcoholic Hepatitis. *Clin Gastroenterol Hepatol*. 2018; 16(10): 1650–1656.e2. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 65. **F** Shasthry SM, Sharma MK, Shasthry V, *et al.*: Efficacy of Granulocyte Colony-stimulating Factor in the Management of Steroid-Nonresponsive Severe Alcoholic Hepatitis: A Double-Blind Randomized Controlled Trial. *Hepatology*. 2019; 70(3): 802–11. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 66. Altamirano J, López-Pelayo H, Michelena J, *et al.*: Alcohol abstinence in patients surviving an episode of alcoholic hepatitis: Prediction and impact on long-term survival. *Hepatology*. 2017; 66(6): 1842–53. [PubMed Abstract](#) | [Publisher Full Text](#)
 67. **F** Louvet A, Labreuche J, Artru F, *et al.*: Main drivers of outcome differ between short term and long term in severe alcoholic hepatitis: A prospective study. *Hepatology*. 2017; 66(5): 1464–73. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 68. Dawson DA, Grant BF, Stinson FS, *et al.*: Effectiveness of the derived Alcohol Use Disorders Identification Test (AUDIT-C) in screening for alcohol use disorders and risk drinking in the US general population. *Alcohol Clin Exp Res*. 2005; 29(5): 844–54. [PubMed Abstract](#) | [Publisher Full Text](#)
 69. Dawson DA, Smith SM, Saha TD, *et al.*: Comparative performance of the AUDIT-C in screening for DSM-IV and DSM-5 alcohol use disorders. *Drug Alcohol Depend*. 2012; 126(3): 384–8. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 70. **F** O'Connor EA, Perdue LA, Senger CA, *et al.*: Screening and Behavioral Counseling Interventions to Reduce Unhealthy Alcohol Use in Adolescents and Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. *JAMA*. 2018; 320(18): 1910–28. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 71. Agabio R, Sinclair JM, Addolorato G, *et al.*: Baclofen for the treatment of alcohol use disorder: The Cagliari Statement. *Lancet Psychiatry*. 2018; 5(12): 957–60. [PubMed Abstract](#) | [Publisher Full Text](#)
 72. **F** Bschor T, Henssler J, Müller M, *et al.*: Baclofen for alcohol use disorder—a systematic meta-analysis. *Acta Psychiatr Scand*. 2018; 138(3): 232–42. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 73. **F** Pierce M, Sutherland A, Beraha EM, *et al.*: Efficacy, tolerability, and safety of low-dose and high-dose baclofen in the treatment of alcohol dependence: A systematic review and meta-analysis. *Eur Neuropsychopharmacol*. 2018; 28(7): 795–806. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 74. **F** Rose AK, Jones A: Baclofen: its effectiveness in reducing harmful drinking, craving, and negative mood. A meta-analysis. *Addiction*. 2018; 113(8): 1396–406. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 75. **F** Jonas DE, Amick HR, Feltner C, *et al.*: Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. *JAMA*. 2014; 311(18): 1889–900. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 76. **F** Parker R, Im G, Jones F, *et al.*: Clinical and microbiological features of infection in alcoholic hepatitis: an international cohort study. *J Gastroenterol*. 2017; 52(11): 1192–200. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 77. Mookerjee RP, Stadlbauer V, Lidder S, *et al.*: Neutrophil dysfunction in alcoholic hepatitis superimposed on cirrhosis is reversible and predicts the outcome. *Hepatology*. 2007; 46(3): 831–40. [PubMed Abstract](#) | [Publisher Full Text](#)
 78. Boussif A, Rolas L, Weiss E, *et al.*: Impaired intracellular signaling, myeloperoxidase release and bactericidal activity of neutrophils from patients with alcoholic cirrhosis. *J Hepatol*. 2016; 64(5): 1041–8. [PubMed Abstract](#) | [Publisher Full Text](#)
 79. **F** Vergis N, Atkinson SR, Knapp S, *et al.*: In Patients With Severe Alcoholic Hepatitis, Prednisolone Increases Susceptibility to Infection and Infection-Related Mortality, and Is Associated With High Circulating Levels of Bacterial DNA. *Gastroenterology*. 2017; 152(5): 1068–1077.e4. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 80. Louvet A, Wartel F, Castet H, *et al.*: Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor. *Gastroenterology*. 2009; 137(2): 541–8. [PubMed Abstract](#) | [Publisher Full Text](#)
 81. Lahmer T, Messer M, Schwerdtfeger C, *et al.*: Invasive mycosis in medical intensive care unit patients with severe alcoholic hepatitis. *Mycopathologia*. 2014; 177(3–4): 193–7. [PubMed Abstract](#) | [Publisher Full Text](#)
 82. Michelena J, Altamirano J, Abalde JG, *et al.*: Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis. *Hepatology*. 2015; 62(3): 762–72. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 83. Mendenhall C, Bongiovanni G, Goldberg S, *et al.*: VA Cooperative Study on Alcoholic Hepatitis. III: Changes in protein-calorie malnutrition associated with 30 days of hospitalization with and without enteral nutritional therapy. *JPEN J Parenter Enteral Nutr*. 1985; 9(5): 590–6. [PubMed Abstract](#) | [Publisher Full Text](#)
 84. Mendenhall CL, Tosch T, Weesner RE, *et al.*: VA cooperative study on alcoholic hepatitis. II: Prognostic significance of protein-calorie malnutrition. *Am J Clin Nutr*. 1986; 43(2): 213–8. [PubMed Abstract](#) | [Publisher Full Text](#)
 85. Moreno C, Deltenre P, Senterre C, *et al.*: Intensive Enteral Nutrition Is Ineffective for Patients With Severe Alcoholic Hepatitis Treated With Corticosteroids. *Gastroenterology*. 2016; 150(4): 903–910.e8. [PubMed Abstract](#) | [Publisher Full Text](#)
 86. Zhong W, McClain CJ, Cave M, *et al.*: The role of zinc deficiency in alcohol-induced intestinal barrier dysfunction. *Am J Physiol Gastrointest Liver Physiol*. 2010; 298(5): G625–G633. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 87. **F** Carey EJ, Lai JC, Wang CW, *et al.*: A multicenter study to define sarcopenia in patients with end-stage liver disease. *Liver Transpl*. 2017; 23(5): 625–33. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 88. Kulkarni SS, Chen H, Josbeno DA, *et al.*: Gait Speed and Grip Strength Are Associated With Dropping Out of the Liver Transplant Waiting List. *Transplant Proc*. 2019; 51(3): 794–7. [PubMed Abstract](#) | [Publisher Full Text](#)
 89. Dunn MA, Josbeno DA, Tevar AD, *et al.*: Frailty as Tested by Gait Speed is an Independent Risk Factor for Cirrhosis Complications that Require Hospitalization. *Am J Gastroenterol*. 2016; 111(12): 1768–75. [PubMed Abstract](#) | [Publisher Full Text](#)
 90. Lai JC, Rahimi RS, Verna EC, *et al.*: Frailty Associated With Waitlist Mortality Independent of Ascites and Hepatic Encephalopathy in a Multicenter Study. *Gastroenterology*. 2019; 156(6): 1675–82. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 91. Wells JT, Said A, Agni R, *et al.*: The impact of acute alcoholic hepatitis in the explanted recipient liver on outcome after liver transplantation. *Liver Transpl*. 2007; 13(12): 1728–35. [PubMed Abstract](#) | [Publisher Full Text](#)
 92. McCallum S, Masterton G: Liver transplantation for alcoholic liver disease: a systematic review of psychosocial selection criteria. *Alcohol Alcohol*. 2006; 41(4): 358–63. [PubMed Abstract](#) | [Publisher Full Text](#)
 93. Pfützmann R, Schwenzler J, Rayes N, *et al.*: Long-term survival and predictors of relapse after orthotopic liver transplantation for alcoholic liver disease. *Liver Transpl*. 2007; 13(2): 197–205. [PubMed Abstract](#) | [Publisher Full Text](#)
 94. DiMartini A, Dew MA, Day N, *et al.*: Trajectories of alcohol consumption following liver transplantation. *Am J Transplant*. 2010; 10(10): 2305–12. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 95. de Gottardi A, Spahr L, Gelez P, *et al.*: A simple score for predicting alcohol relapse after liver transplantation: results from 387 patients over 15 years. *Arch Intern Med*. 2007; 167(11): 1183–8. [PubMed Abstract](#) | [Publisher Full Text](#)
 96. **F** Mathurin P, Moreno C, Samuel D, *et al.*: Early liver transplantation for severe alcoholic hepatitis. *N Engl J Med*. 2011; 365(19): 1790–800. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 97. Im GY, Kim-Schluger L, Shenoy A, *et al.*: Early Liver Transplantation for Severe Alcoholic Hepatitis in the United States—A Single-Center Experience. *Am J Transplant*. 2016; 16(3): 841–9. [PubMed Abstract](#) | [Publisher Full Text](#)
 98. **F** Lee BP, Chen PH, Haugen C, *et al.*: Three-year Results of a Pilot Program in Early Liver Transplantation for Severe Alcoholic Hepatitis. *Ann Surg*. 2017; 265(1): 20–9. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 99. **F** Lee BP, Mehta N, Platt L, *et al.*: Outcomes of Early Liver Transplantation for Patients With Severe Alcoholic Hepatitis. *Gastroenterology*. 2018; 155(2): 422–430.e1. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 100. **F** Lee BP, Samur S, Dalgic OO, *et al.*: Model to Calculate Harms and Benefits of Early vs Delayed Liver Transplantation for Patients With Alcohol-Associated Hepatitis. *Gastroenterology*. 2019; 157(2): 472–480.e5. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 101. **F** Lee BP, Vittinghoff E, Hsu C, *et al.*: Predicting Low Risk for Sustained Alcohol Use After Early Liver Transplant for Acute Alcoholic Hepatitis: The Sustained Alcohol Use Post-Liver Transplant Score. *Hepatology*. 2019; 69(4): 1477–87. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. **Philip Augustine**

Department of Gastroenterology, Cochin Gastroenterology Group, Ernakulam Medical Centre, Cochin, Kerala, India

Competing Interests: No competing interests were disclosed.

2. **Sandeep Singh Sidhu**

Department of Gastroenterology, Dayanand Medical College and Hospital, Ludhiana, Punjab, India

Competing Interests: No competing interests were disclosed.

3. **Suthat Liangpunsakul**

Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research